Biohit Oyj - Company Announcement

Biohit has implemented Euroclone acquisition, new company will start as Italian subsidiary

Biohit Oyj 18.04.2013 at 4:30 P.M. local time



Biohit Oyj announces the closing of Euroclone acquisition today. The new
company, Biohit Italy S.r.l., will begin operations as a Biohit subsidiary
focusing on marketing and distribution of company's  diagnostic products in
Italy. New subsidiary has distribution network and market knowledge of Italian
market. 

The acquisition was closed and the share issue was subscribed in accordance
with the exchange rate of the day prior to the closing (17 April 2013) thus
resulting as the value of the acquisition 1 126 800,00 €. The new shares will
be registered with Euroclear system approximately between 29 April 2013 and 6
May 2013. The restrictions related to the transfer of the shares have been
published earlier. 




New organization structure and management

Biohit has from April 18, 2013 onwards three subsidiaries: UK, China and Italy.
The new subsidiary will initially have 2 employees, which increases the number
of the Group's staff to 37. Franco Aiolfi has been appointed to subsidiary CEO. 



Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealthcare.com



Biohit in brief

Biohit Oyj is a Finnish biotechnology company operating globally that was
established in 1988. Biohit's mission is "Innovating for Health". The purpose
of the company is to take social responsibility and produce innovation, new
technologies and analysis systems for use in medicine, research institutions
and industry, helping to promote research and diagnostics and to improve the
quality of life of people by means of preventing disease, human suffering and
financial loss. We are committed to social responsibility and it is our duty to
spread knowledge about the Group 1 human carcinogen, acetaldehyde, and innovate
and develop the marketing and availability of our products and services. Biohit
is headquartered in Helsinki and its subsidiaries are located in China and the
United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed
in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.